Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.42 |
| ▸ | EGFR | P00533 | 4/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3679530 | 0.84 | L3MBTL1 (0.45) | MAOBMAOAKDM4EL3MBTL1NPC1 | |
| SCHEMBL5872212 | 0.84 | MAOB (0.41) | MAOBEGFRERBB2POLBMAOA | |
| SCHEMBL5871986 | 0.84 | RXRA (0.36) | KMT2A | |
| SCHEMBL498618 | 0.83 | KMT2A (0.53) | MAPTKMT2AHPGDSMN1; SMN2 | |
| SCHEMBL5872082 | 0.82 | SMN1; SMN2 (0.46) | EGFRERBB2MEN1MAPTKMT2A | |
| SCHEMBL6244263 | 0.80 | KIF11 (0.49) | MAOBKDM4EL3MBTL1KMT2A | |
| SCHEMBL3677944 | 0.80 | MAPT (0.47) | NPC1MEN1MAPTKMT2ACYP1A2 | |
| SCHEMBL9340202 | 0.79 | EGFR (0.40) | EGFRERBB2POLBNPC1MEN1 | |
| SCHEMBL6236255 | 0.76 | TSHR (0.47) | KDM4EMEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL21632567 | 0.73 | EGFR (0.46) | MAOBEGFRERBB2POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619185-A1 | MATRIX METALLOPROTEINASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012038942-A1 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2012-03-29 | — | — | WO | disclosed |
| EP-1223923-B1 | UNSATURATED ARYL SULFONES FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | UNIV TEMPLE (US) | 2010-03-31 | — | — | EP | disclosed |
| US-7595347-B2 | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents | Temple University—Of the Commonwealth System of Higher Education (US) | 2009-09-29 | — | — | US | disclosed |
| EP-1223923-A4 | METHOD FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | UNIV TEMPLE (US) | 2007-09-05 | — | — | EP | disclosed |
| US-7056953-B2 | (E)-styryl sulfone anticancer agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1173160-B1 | (E)-STYRYL SULFONE ANTICANCER AGENTS | UNIV TEMPLE (US) | 2005-06-22 | — | — | EP | disclosed |
| EP-1027330-B1 | STYRYL SULFONE ANTICANCER AGENTS | UNIV TEMPLE (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040229959-A1 | (E)-styryl sulfone anticancer agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2004-11-18 | — | — | US | disclosed |
| US-20040214903-A1 | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents | COSENZA STEPHEN C (US) | 2004-10-28 | — | — | US | disclosed |
| EP-1173160-A4 | (E)-STYRYL SULFONE ANTICANCER AGENTS | UNIV TEMPLE (US) | 2003-02-19 | — | — | EP | disclosed |
| EP-1223923-A1 | METHOD FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | Temple University of the Commonwealth System of Higher Education (US) | 2002-07-24 | — | — | EP | disclosed |
| US-6359013-B1 | BREAST AND PROSTATE CANCER; AFFECT THE MAPK SIGNAL TRANSDUCTION PATHWAY, THEREBY TUMOR CELL GROWTH; INHIBIT THE GROWTH OF TUMOR CELLS WITHOUT AFFECTING NORMAL CELLS; 4-FLUOROSTYRYL 4-BROMOBENZYL SULFONE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2002-03-19 | — | — | US | disclosed |
| US-20020022666-A1 | Styryl sulfone anticancer agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2002-02-21 | — | — | US | disclosed |
| EP-1173160-A1 | (E)-STYRYL SULFONE ANTICANCER AGENTS | Temple University of the Commonwealth System of Higher Education (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2001026645-A1 | METHOD FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2001-04-19 | — | — | WO | disclosed |
| WO-2000059494-A1 | STYRYL SULFONE ANTICANCER AGENTS | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2000-10-12 | — | — | WO | disclosed |
| WO-2000059495-A1 | (E)-STYRYL SULFONE ANTICANCER AGENTS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2000-10-12 | — | — | WO | disclosed |
| EP-1027330-A1 | STYRYL SULFONE ANTICANCER AGENTS | Temple University of the Commonwealth System of Higher Education (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999018068-A1 | STYRYL SULFONE ANTICANCER AGENTS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214903-A1 | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents | TOP1, TOP2A, PCNA | MAOB 3501/4885EGFR 3709/4885ERBB2 4182/4885 |
| US-20020022666-A1 | Styryl sulfone anticancer agents | BCL2, MCL1, BCL2A1 | MAOB 3488/4885EGFR 264/4885ERBB2 106/4885 |
| US-20040229959-A1 | (E)-styryl sulfone anticancer agents | SULT1E1, CCNE1, RPS3A | MAOB 3806/4885EGFR 330/4885ERBB2 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.